| Functional genomic landscape of acute myeloid leukaemia JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ... Nature 562 (7728), 526-531, 2018 | 1052 | 2018 |
| Integrative analysis of drug response and clinical outcome in acute myeloid leukemia D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon, K Johnson, M Abel, ... Cancer Cell 40 (8), 850-864. e9, 2022 | 103 | 2022 |
| Natural product target network reveals potential for cancer combination therapies SR Chamberlin, A Blucher, G Wu, L Shinto, S McWeeney Frontiers in pharmacology 10, 452365, 2019 | 53 | 2019 |
| Phase Ib dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple-negative breast, and ovarian cancer SN Westin, M Labrie, JK Litton, A Blucher, Y Fang, CP Vellano, ... Clinical Cancer Research 27 (23), 6354-6365, 2021 | 33 | 2021 |
| An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer BE Johnson, AL Creason, JM Stommel, JM Keck, S Parmar, CB Betts, ... Cell Reports Medicine 3 (2), 2022 | 27 | 2022 |
| Evidence-based precision oncology with the cancer targetome AS Blucher, G Choonoo, M Kulesz-Martin, G Wu, SK McWeeney Trends in pharmacological sciences 38 (12), 1085-1099, 2017 | 27 | 2017 |
| Visualization of drug target interactions in the contexts of pathways and networks with ReactomeFIViz AS Blucher, SK McWeeney, L Stein, G Wu F1000Research 8, 2019 | 20 | 2019 |
| Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies M Labrie, A Li, A Creason, C Betts, J Keck, B Johnson, S Sivagnanam, ... NPJ precision oncology 5 (1), 92, 2021 | 11 | 2021 |
| Precision oncology for breast cancer through clinical trials AS Blucher, GB Mills, YH Tsang Clinical & Experimental Metastasis 39 (1), 71-78, 2022 | 10 | 2022 |
| Challenges in secondary analysis of high throughput screening data AS Blucher, SK McWeeney Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 114, 2014 | 10 | 2014 |
| Functional genomic analysis identifies drug targetable pathways in invasive and metastatic cutaneous squamous cell carcinoma AN Anderson, D McClanahan, J Jacobs, S Jeng, M Vigoda, AS Blucher, ... Molecular Case Studies 6 (4), a005439, 2020 | 6 | 2020 |
| IMP1/IGF2BP1 in human colorectal cancer extracellular vesicles M Kuhn, Y Zhang, J Favate, M Morita, A Blucher, S Das, S Liang, R Preet, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 323 (6 …, 2022 | 5 | 2022 |
| Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer SY Park, KJ Jeong, A Poire, D Zhang, YH Tsang, AS Blucher, GB Mills Cell Death & Disease 14 (8), 532, 2023 | 4 | 2023 |
| An integrated clinical, omic, and image atlas of an evolving metastatic breast cancer BE Johnson, AL Creason, JM Stommel, J Keck, S Parmar, CB Betts, ... bioRxiv 2020, 12.03, 2020 | 4 | 2020 |
| Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma G Choonoo, AS Blucher, S Higgins, M Boardman, S Jeng, C Zheng, ... PloS one 14 (10), e0223639, 2019 | 4 | 2019 |
| Mathematical modeling of integrin dynamics in initial formation of focal adhesions A Blucher, M Salas, N Williams, H Callender Involve, a Journal of Mathematics 7 (4), 509-527, 2014 | 4 | 2014 |
| Mapping biology with a unified representation space for genomic and chemical perturbations to enable accelerated drug discovery AS Blucher, S Celik, JD Jensen, J Taylor, MF Cuccarese, JC Cooper, ... Learning Meaningful Representation of Life Workshop at NeurIPS, 2021 | 2 | 2021 |
| Which path to follow? Utilizing proteomics to improve therapy choices for breast cancer patients AS Blucher, GB Mills, YH Tsang Expert Review of Proteomics 17 (3), 187-190, 2020 | 1 | 2020 |
| Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations M Labrie, A Li, A Creason, C Betts, J Keck, B Johnson, S Sivagnanam, ... medRxiv, 2020 | 1 | 2020 |
| Abstract LB071: A phenomics platform combining imaging and artificial intelligence for rapid validation and advancement of novel oncology targets J Rudnick, K Nadella, C Neumann, S Rowley, E Gardner, S Swaidani, ... Cancer Research 83 (8_Supplement), LB071-LB071, 2023 | | 2023 |
Shannon McWeeneyProfessor & Vice-Chair, Oregon Health and Science University | Chief Data Officer, OHSU KnightVerified email at ohsu.edu
